Insmed revealed that Japan has more patients with MAC lung disease than the entire U.S., expanding the potential market for its ARIKAYCE therapy from 30,000 to over 200,000 patients if approved as a first-line treatment. The ENCORE Phase 3b trial showed positive results for ARIKAYCE as a first-line therapy, with a supplemental FDA and Japan filing planned for late 2026 and commercial impact expected in 2027. Japan already drives strong growth, contributing over 25% of global ARIKAYCE revenue with rapid year-over-year increases in 2025. This new data and market insight transform Insmed's growth outlook, shifting focus to the size of the opportunity rather than ARIKAYCE's growth potential.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
